Biogen, its place in the healthcare and biotechnology sector and full sector report
Includes full sector report with 17 healthcare and biotechnology companies, where Biogen is analysed in relative perspective of Abbott Laboratories, Abbvie, Amgen, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Co, Eli Lilly Co, Gilead Sciences, GlaxoSmithKline plc, Johnson & Johnson, Merck, Novartis, Novo Nordisk A/S, Pfizer, Roche Holding ltd. Gnns and Sanofi. Ready to implement with standard portfolio. This report makes it clear how to allocate funds within the healthcare and biotechnology sector and drives your outperformance. Targeted and expected outperformance is 10% per year on the upper half of companies and 5% per year on a diversified standard portfolio in the sector based on long term results and experience.
Biogen is a biopharmaceutical company focused on discovering, developing and delivering therapies for people living with neurological and neurodegenerative diseases as well as related therapeutic adjacencies. The company's main growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer's disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis; movement disorders, including Parkinson's disease; and ophthalmology. The company's marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis.
Analist is and analysis by drs. E. (Erik) D. Molenaar RBA, RBA/CFA certified investment analist and EFFAS certified financial analist. Delivering to the point investment analysis. Apart from an absolute advice, a clear sector advice and overview, and/or a relative advice within the sector, is always included in the reports which makes the reports extremely usefull and helpfull for fund allocation within a sector.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.